翠華控股(01314.HK)年度預虧約1.6億至1.8億港元
格隆匯4月29日丨翠華控股(01314.HK)發佈公告,集團預期於截至2020年3月31日止年度將錄得虧損合共介乎約為1.6億港元至1.8億港元,而2019年度則錄得除税後溢利約為470.9萬港元。
公告表示,虧損主要由於(i)部分資產預計將錄得一次性撇銷及╱或減值虧損等非現金性項目合共介乎約為2000萬港元至3000萬港元;(ii)資產折舊及攤銷合共約1億港元;(iii)自2019年6月中旬起(尤其自爆發新型冠狀病毒(COVID-19)大流行以來)入境旅客及出外用膳的巿民鋭減以致本年度的收益下跌;及(iv)食材成本等經營成本持續上漲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.